Compare SQNS & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SQNS | PMVP |
|---|---|---|
| Founded | 2003 | 2013 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.9M | 71.1M |
| IPO Year | 2011 | 2020 |
| Metric | SQNS | PMVP |
|---|---|---|
| Price | $2.73 | $1.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $10.00 | $4.20 |
| AVG Volume (30 Days) | 35.4K | ★ 515.8K |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $33.92 | N/A |
| Revenue Next Year | $66.21 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.38 | $1.02 |
| 52 Week High | $10.19 | $1.88 |
| Indicator | SQNS | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 68.53 |
| Support Level | $2.72 | $1.05 |
| Resistance Level | $3.19 | $1.88 |
| Average True Range (ATR) | 0.17 | 0.11 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 1.20 | 89.89 |
Sequans Communications SA is a fabless semiconductor company specializing in wireless 4G and 5G cellular technologies for the Internet of Things (IoT). Sequans' engineers design and develop, secure, and energy-efficient semiconductor solutions that enable the next generation of AI-connected applications, including smart energy metering, industrial automation, smart mobility and logistics, secure payments, e-health, and smart home solutions. The Company offers a comprehensive portfolio of wireless connectivity solutions, including radio frequency (RF) transceivers, integrated circuits (ICs) for baseband processing, as well as modules, software, & protocol stacks. The Company has one operating segment, which is the design & marketing of semiconductor components for cellular wireless systems.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.